A novel nasal spray vaccine targeting Bordetella pertussis, the causative agent of whooping cough, has demonstrated potential in enhancing both disease prevention and infection control. Despite the availability of pertussis vaccines for over 80 years, there remains a critical need for improved efficacy, particularly in preventing transmission. Kingston Mills, PhD, from Trinity College Dublin, highlighted the limitations of existing vaccines, which, while effective at preventing severe symptoms, fail to stop infection and its spread.
Mills and his team have focused on leveraging local immune responses by developing a vaccine that activates T cells in the nasal mucosa. Their innovative approach employs antibiotic-inactivated bacteria, specifically using ciprofloxacin and levofloxacin, to maintain bacterial integrity while enhancing immunogenicity. Initial preclinical trials in mice indicate that this method not only outperforms traditional vaccines but also minimizes systemic inflammatory responses, suggesting a safer profile.
As the team prepares for clinical trials, they aim to refine production methods that could easily scale for broader applications. This research could pave the way for more effective vaccines against various bacterial infections, simplifying the development process and potentially transforming vaccine delivery strategies in the future.
Get started today with Solo access →
